A novel pharmacokinetic method for analysis of placental transfer of latamoxef in humans.
A novel pharmacokinetic method was developed for analysing the behaviour of a drug in tissues. The absolute transfer ratio of a drug to a tissue was defined using the pharmacokinetic parameters obtained by this method. Composite data of latamoxef (moxalactam) concentration in maternal blood, umbilical cord blood and amniotic fluid following a 2g intravenous injection to pregnant women at delivery were analysed by this method to study the drug behaviour in pregnant women, fetuses and amniotic fluid. Latamoxef kinetics in pregnant women at full term were generally similar to that in previously reported healthy subjects. The concentration of latamoxef in umbilical cord blood peaked about 2 hours after dosing then decreased in parallel with the maternal blood concentration. The amniotic fluid concentration peaked about 7 hours after administration, then decreased slowly. The absolute transfer ratios to fetus and amniotic fluid were calculated to be about 2.5 and 0.37% respectively.
D000653:Amniotic Fluid / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008431:Maternal-Fetal Exchange; D008433:Mathematics; D008954:Models, Biological; D009070:Moxalactam / Q000097:blood / Q000378:metabolism*; D011247:Pregnancy; D014018:Tissue Distribution
D009070:Moxalactam